Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPPC-Q7-doxorubicin
- Development stage
- Preclinical
- Lead developer
- National Yang Ming Chiao Tung University
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
**LPPC-Q7-doxorubicin** is an investigational, co-encapsulated lipoplex nanocomplex comprising the 15-amino-acid anticancer peptide Q7 and the anthracycline chemotherapy agent doxorubicin. The Lipo-PEG-PEI complex nanoparticle carrier improves Q7 delivery and stability while providing sustained release of both payloads. In preclinical endometrial-cancer models, Q7 suppresses 24-dehydrocholesterol reductase and associated cholesterol-dependent AKT signaling, reducing proliferation, migration, invasion, exosome-associated signaling, and metastasis markers; doxorubicin contributes DNA damage through topoisomerase II inhibition and DNA intercalation. The combined formulation showed synergistic antitumor activity in HEC-1-A endometrial-cancer cells and mouse xenografts following intravenous administration.
- Other names
- LPPC-Q7-DOXLPPC-Q-7-DOXLPPC-Q 7-DOX
02
Targets
TOP2A (DNA topoisomerase II)AKT (RAC-alpha serine/threonine-protein kinase)DHCR24 (3β-hydroxysterol Δ24-reductase)DNA
Beyond the preview
Go deeper on LPPC-Q7-doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPPC-Q7-doxorubicin.